Thuja Capital Healthcare Seed Fund II | funds

Portfolio Thuja Capital Healthcare Seed Fund II

Company: NutriLeads - Visit website

Fund: Thuja Capital Healthcare Seed Fund II

Year: 2015

Status: Active

Wageningen based company active in the field of medical nutrition and functional foods. Currently develops a food ingredient with immune system enhancing properties to help combat infections.

Company: Encare Biotech - Visit website

Fund: Thuja Capital Healthcare Seed Fund II

Year: 2014

Status: Active

Encare Biotech is a spin-off of Utrecht UMC, dedicated to develop antibody therapeutics to prevent chronic heart failure as a consequence of a myocardial infarction.

News
- 18 May 2017, Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX, Nasdaq: ARGX) announced today the pricing of its initial public offering in the United States (the “Offering”) with anticipated gross proceeds totalling approximately $100 million from the sale of 5,865,000 American Depository Shares (“ADSs”), at a price to the public of $17.00 per ADS. Read further …
- 29 March 2017, Wageningen, The Netherlands -Dutch nutritional health ingredients startup NUTRILEADS B.V. today announces the successful closing of a Series A financing round with existing shareholders DSM VENTURING, PPM OOST, SHIFT INVEST and THUJA CAPITAL. Read further …
- 21 March 2017, Breda, the Netherlands/Ghent, Belgium – argenx (Euronext Brussels: ARGX) today announced that it has entered into a new collaboration with Broteio Pharma B.V. to develop an antibody against a novel target in the complement cascade with therapeutic potential in autoantibody- and complement-mediated indications including autoimmune haemolytic anaemia (AIHA) and antibody mediated rejection (AMR) following organ transplantation. Read further …